Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
Authors:
Open Access
- 27 October 2023
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-11
Abstract
Background: The Italian Medicines Agency (AIFA) demands precise information on benefit/risk profile of home-based enzyme replacement therapy (ERT) for the treatment of patients with Pompe disease and Mucopolysaccharidosis type I (MPS I). This passage is necessary to obtain the authorization for ERT home therapy, even after the coronavirus disease-19 (COVID-19) pandemic period. This research intends to evaluate the safety, treatment satisfaction, and compliance of MPS I patients treated with laronidase (Aldurazyme®) and Pompe Disease patients treated with alglucosidase alfa (Myozyme®) in a homecare setting.Results: We report herein an early interim analysis of the HomERT (Home infusions of ERT) study, a multicenter, non-interventional, double-cohort study that retrospectively analyzed 38 patients from 14 sites in Italy: cohort A (Pompe disease − 32 patients) and cohort B (MPS I − 6 patients). Among the selected patients who started home therapy before enrollment, the average number of missed home-based infusions was 0.7 (1.3) in cohort A and 3.8 (6.4) in cohort B with no return to the hospital setting. Irrespective of the treatment location, 3 prior ADRs per cohort were reported. The majority of patients preferred home-based infusions (cohort A: 96.9%; cohort B: 100%): the main reason was attributed to treatment convenience (cohort A: 81.3%; cohort B: 83.3%). Despite the underlying conditions, most patients self-evaluated their health as “good” (cohort A: 50%; cohort B: 83.3%).Conclusions: Evidence of favorable safety profile, improved treatment compliance and personal satisfaction validates the use of ERT with laronidase and alglucosidase alfa as a strong candidate for home therapy.Keywords
Funding Information
- Sanofi (Sanofi)
This publication has 27 references indexed in Scilit:
- Effect of rapid cessation of enzyme replacement therapy: A report of 5 cases and a review of the literatureMolecular Genetics and Metabolism, 2012
- Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)Molecular Genetics and Metabolism, 2011
- The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populationsJournal of Inherited Metabolic Disease, 2010
- Home treatment with Elaprase® and Naglazyme® is safe in patients with mucopolysaccharidoses types II and VI, respectivelyJournal of Inherited Metabolic Disease, 2008
- Home therapy for lysosomal storage disordersBritish Journal of Nursing, 2007
- Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapyAmerican Journal of Medical Genetics Part A, 2007
- Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type IJournal of Inherited Metabolic Disease, 2006
- Home treatment for Fabry disease: practice guidelines based on 3 years experience in The NetherlandsNephrology Dialysis Transplantation, 2005
- Prevalence of lysosomal storage diseases in PortugalEuropean Journal of Human Genetics, 2003
- The frequency of lysosomal storage diseases in The NetherlandsHuman Genetics, 1999